Latest Conference Articles

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

Atezolizumab plus bevacizumab could yield superior outcomes compared with TACE in intermediate-stage HCC.

Results from ReFocus showed a manageable safety profile and positive antitumor activity for lirafugratinib in FGFR2-mutated cholangiocarcinoma.

Marcel Verheij, MD, PhD, discusses the use of chemotherapy vs CRT-containing strategies as a preferred preoperative regimen for resectable gastric cancer.

Neoadjuvant tislelizumab plus chemoradiotherapy yielded improved response rates in gastric cancer and gastroesophageal junction adenocarcinoma.

Adjuvant pembrolizumab did not improve RFS vs placebo in HCC following complete radiological response after surgical resection or local ablation.

Stephen Lam Chan, MBBS, MD (CUHK), FRCP, discusses the lack of benefit with adjuvant pembrolizumab in HCC following a complete radiologic response.

CAR-like T-cells, PD-1 inhibitor, and SOX was active in previously untreated metastatic gastric or GEJ adenocarcinoma.

ECOG performance status captured only part of the patient experience in advanced gastric or gastroesophageal junction adenocarcinoma.

Elena Elimova, MD, discusses efficacy data for zanidatamab in HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.

Total neoadjuvant chemotherapy plus chemoradiotherapy was identified as a preferred candidate for future study in resectable gastric adenocarcinoma.

Shuqiang Yuan, MD, PhD, outlines the most important data after 3 years of follow-up from the NEOSUMMIT-01 trial in locally advanced gastric/GEJ cancer.

Zolbetuximab plus mFOLFOX6 and nivolumab was effective and tolerable across biomarker-defined subgroups in unresectable gastric/GEJ adenocarcinoma.

HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.

NXC-201 demonstrated organ responses in 70% of evaluable patients with relapsed/refractory light chain amyloidosis.

Real-world elranatamab led to higher response rates despite less favorable baseline characteristics vs real-world teclistamab in R/R multiple myeloma.

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

Glofitamab and epcoritamab were both associated with early disease progression in relapsed/refractory large B-cell lymphoma.

Tumor burden and disease status were not correlated with CRS risk or severity in newly diagnosed, relapsed/refractory myeloma managed with elranatamab.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.